Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
6 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Long-Term Benefits from Early Antiretroviral Therapy Initiation in HIV Infection.
NEJM Evid. 2023 Mar;2(3):10.1056/evidoa2200302. doi: 10.1056/evidoa2200302. Epub 2023 Feb 27.
NEJM Evid. 2023.
PMID: 37213438
Free PMC article.
Service delivery challenges in HIV care during the first year of the COVID-19 pandemic: results from a site assessment survey across the global IeDEA consortium.
Brazier E, Ajeh R, Maruri F, Musick B, Freeman A, Wester CW, Lee MP, Shamu T, Crabtree Ramírez B, d'Almeida M, Wools-Kaloustian K, Kumarasamy N, Althoff KN, Twizere C, Grinsztejn B, Tanser F, Messou E, Byakwaga H, Duda SN, Nash D; International epidemiology Databases to Evaluate AIDS.
Brazier E, et al.
J Int AIDS Soc. 2022 Dec;25(12):e26036. doi: 10.1002/jia2.26036.
J Int AIDS Soc. 2022.
PMID: 36504431
Free PMC article.
Item in Clipboard
Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial.
Cahn P, Kaplan R, Sax PE, Squires K, Molina JM, Avihingsanon A, Ratanasuwan W, Rojas E, Rassool M, Bloch M, Vandekerckhove L, Ruane P, Yazdanpanah Y, Katlama C, Xu X, Rodgers A, East L, Wenning L, Rawlins S, Homony B, Sklar P, Nguyen BY, Leavitt R, Teppler H; ONCEMRK Study Group.
Cahn P, et al.
Lancet HIV. 2017 Nov;4(11):e486-e494. doi: 10.1016/S2352-3018(17)30128-5. Epub 2017 Sep 11.
Lancet HIV. 2017.
PMID: 28918877
Clinical Trial.
Item in Clipboard
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.
INSIGHT START Study Group; Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, Avihingsanon A, Cooper DA, Fätkenheuer G, Llibre JM, Molina JM, Munderi P, Schechter M, Wood R, Klingman KL, Collins S, Lane HC, Phillips AN, Neaton JD.
INSIGHT START Study Group, et al.
N Engl J Med. 2015 Aug 27;373(9):795-807. doi: 10.1056/NEJMoa1506816. Epub 2015 Jul 20.
N Engl J Med. 2015.
PMID: 26192873
Free PMC article.
Clinical Trial.
Item in Clipboard
Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study.
ENCORE1 Study Group; Carey D, Puls R, Amin J, Losso M, Phanupak P, Foulkes S, Mohapi L, Crabtree-Ramirez B, Jessen H, Kumar S, Winston A, Lee MP, Belloso W, Cooper DA, Emery S.
ENCORE1 Study Group, et al.
Lancet Infect Dis. 2015 Jul;15(7):793-802. doi: 10.1016/S1473-3099(15)70060-5. Epub 2015 Apr 12.
Lancet Infect Dis. 2015.
PMID: 25877963
Clinical Trial.
Item in Clipboard
Why START? Reflections that led to the conduct of this large long-term strategic HIV trial.
INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group; Lundgren J, Babiker A, Gordin F, Emery S, Fätkenheuer G, Molina JM, Wood R, Neaton JD.
INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group, et al.
HIV Med. 2015 Apr;16 Suppl 1(0 1):1-9. doi: 10.1111/hiv.12227.
HIV Med. 2015.
PMID: 25711317
Free PMC article.
No abstract available.
Item in Clipboard
Cite
Cite